Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic…
SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI... Read more.
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
– Company Now Exclusively Focused on Development and Commercialization of Abecma – CAMBRIDGE, Mass.–(BUSINESS WIRE)–#TSVT—2seventy... Read more.
Freedom Holding Corp. CEO, Timur Turlov, to Deliver Keynote Speech at LD Micro Inaugural New York Investor Conference
Freedom Capital Markets NYC Family Office Summit Attendance Also on CEO Schedule ALMATY, Kazakhstan & NEW YORK–(BUSINESS WIRE)–Freedom Holding Corp.... Read more.
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Novum IQ Infusion Platform now offers large volume and syringe infusion smart pumps on an integrated system with shared innovative digital health solutions to help... Read more.
Ellington Residential Announces Strategic Transformation
– Focus on CLO Investments Expected to Enhance Earnings, Reduce Volatility and Drive Book Value Growth, Utilizing Less Leverage – – Company Revokes... Read more.
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative... Read more.
Guess?, Inc. Announces Issuance of Approximately $12.1 Million of Additional 3.75% Convertible Notes Due 2028 and Retirement of Approximately $14.6 Million of Existing 2.00% Convertible Notes Due 2024
The additional convertible senior notes due 2028 issued in exchange for our existing convertible senior notes due 2024 will augment the exchange and subscription... Read more.
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received... Read more.
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies... Read more.
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
— Companies will co-develop inhibitors of a dark kinase target (NEK1) identified for cancer dependency by Turbine’s Simulated Cell™ platform — LONDON &... Read more.